Share on StockTwits

Pfizer (NYSE:PFE) EVP Laurie J. Olson unloaded 36,275 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $29.53, for a total transaction of $1,071,200.75. Following the completion of the sale, the executive vice president now directly owns 56,735 shares of the company’s stock, valued at approximately $1,675,385. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Pfizer (NYSE:PFE) traded up 0.02% during mid-day trading on Friday, hitting $29.455. 11,847,406 shares of the company’s stock traded hands. Pfizer has a 52 week low of $27.33 and a 52 week high of $32.96. The stock’s 50-day moving average is $29.80 and its 200-day moving average is $30.86. The company has a market cap of $187.9 billion and a price-to-earnings ratio of 9.14. Pfizer also was the recipient of a large decrease in short interest during the month of May. As of May 30th, there was short interest totalling 56,694,370 shares, a decrease of 5.3% from the May 15th total of 59,856,772 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average trading volume of 26,841,182 shares, the short-interest ratio is presently 2.1 days.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, May 5th. The company reported $0.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.01. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter last year, the company posted $0.54 earnings per share. Pfizer’s revenue was down 8.5% compared to the same quarter last year. Analysts expect that Pfizer will post $2.24 EPS for the current fiscal year.

A number of analysts have recently weighed in on PFE shares. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Pfizer in a research note on Wednesday, May 28th. They set an “overweight” rating and a $35.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, May 27th. They now have a $31.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Pfizer in a research note on Tuesday, May 27th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Buy” and an average target price of $32.83.

Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.